EagleClaw Capital Managment LLC Has $2.54 Million Stock Position in Sanofi $SNY

EagleClaw Capital Managment LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 14.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,585 shares of the company’s stock after buying an additional 6,760 shares during the period. EagleClaw Capital Managment LLC’s holdings in Sanofi were worth $2,540,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of SNY. Voya Investment Management LLC grew its position in Sanofi by 11.6% in the 1st quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after purchasing an additional 21,540 shares during the last quarter. Ascent Group LLC bought a new stake in shares of Sanofi in the first quarter valued at about $426,000. 1248 Management LLC acquired a new stake in Sanofi during the first quarter worth about $518,000. Equity Investment Corp increased its stake in Sanofi by 2.5% during the second quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock valued at $121,376,000 after acquiring an additional 62,109 shares during the period. Finally, Simon Quick Advisors LLC acquired a new position in Sanofi in the 2nd quarter valued at approximately $246,000. 14.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SNY. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Up 0.4%

Shares of NASDAQ SNY opened at $51.92 on Thursday. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06. The business has a fifty day moving average of $48.75 and a two-hundred day moving average of $49.45. The stock has a market cap of $127.49 billion, a PE ratio of 12.16, a PEG ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $14.53 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the company posted $2.25 EPS. The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. As a group, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.